Platelet-rich plasma as treatment for persistent ocular epithelial defects.
Platelet- rich plasma (PRP) exhibits regenerative proprieties in wound healing but the biochemical mechanisms are unclear. In this study, autologous PRP with a mean value of 338 × 10(3) platelets/µL was used to treat corneal lesions of different aetiology, while homologous PRP with 1 × 10(6) platelets/µL was used to treat cornel lesions induced by a graft versus host disease. The impact of platelet count on the levels of PDGF AA and BB, VEGF, and EGF in the two PRPs was evaluated after a cycle of freezing/thawing. Treated corneal lesions healed or improved. The levels of PDGF AA and BB, VEGF, and EGF in the autologous PRP raised from 296 ± 61; 201.8 ± 24; 53 ± 14 and 8.9 ± 2 to 1017 ± 253; 924.7 ± 222; 101 ± 46.5 and 174 ± 15.5 pg/mL, while in the homologous PRP were 3.4, 4.5, 3.2 and 2 folds higher, respectively. High level of platelet counts seems not required to treat corneal lesions.
UOSD SIMT, Policlinico Tor Vergata Foundation, Roma, Italy.
Corrado
C
Ronci
UOSD SIMT, Policlinico Tor Vergata Foundation, Roma, Italy.
Angelo Salvatore
AS
Ferraro
UOSD SIMT, Policlinico Tor Vergata Foundation, Roma, Italy. Electronic address: ale.lanti@libero.it.
Alessandro
A
Lanti
Department of Ophtalmology, University of Rome Tor Vergata, Roma, Italy.
Filippo
F
Missiroli
UOSD SIMT, Policlinico Tor Vergata Foundation, Roma, Italy.
Silvia
S
Sinopoli
UOSD SIMT, Policlinico Tor Vergata Foundation, Roma, Italy.
Gianpaolo
G
Del Proposto
UOSD SIMT, Policlinico Tor Vergata Foundation, Roma, Italy.
Chiara
C
Cipriani
Department of Ophtalmology, University of Rome Tor Vergata, Roma, Italy.
Cecilia
C
De Felici
Department of Ophtalmology, University of Rome Tor Vergata, Roma, Italy.
Federico
F
Ricci
Laboratory of Molecular Virology, Policlinico Tor Vergata Foundation, Roma, Italy.
Marco
M
Ciotti
Department of Hematology, Stem Cell Transplant Unit, University of Rome Tor Vergata, Roma, Italy.
Laura
L
Cudillo
Department of Hematology, Stem Cell Transplant Unit, University of Rome Tor Vergata, Roma, Italy.
William
W
Arcese
UOSD SIMT, Policlinico Tor Vergata Foundation, Roma, Italy.
Gaspare
G
Adorno
D000077214:Becaplermin; D001792:Blood Platelets / Q000166:cytology; D001793:Blood Preservation / Q000379:methods; D003320:Corneal Ulcer / Q000628:therapy*; D015925:Cryopreservation; D005260:Female; D005615:Freezing; D006801:Humans; D008297:Male; D008875:Middle Aged; D024101:Mitochondrial Proteins / Q000097:blood; D009883:Ophthalmic Solutions; D020653:Peptide Elongation Factor G / Q000097:blood; D015539:Platelet Activation; D010976:Platelet Count; D010982:Platelet-Derived Growth Factor / Q000378:metabolism; D053657:Platelet-Rich Plasma; D020574:Proto-Oncogene Proteins c-sis / Q000097:blood; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000097:blood; D014945:Wound Healing
C441680:GFM1 protein, human; D024101:Mitochondrial Proteins; D009883:Ophthalmic Solutions; D020653:Peptide Elongation Factor G; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; C075278:platelet-derived growth factor A; D000077214:Becaplermin
Corneal ulcers; Eye drops; Growth factors; Platelet-rich plasma